Star Metro - Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors

Mr. Mastrodonato brings extensive leadership and international business development experience in the pharmaceutical and biotechnology industries. He was the former Co-Founder and Executive Director of Sinclair Pharma plc., a publicly listed pharmaceutical company on the London Stock Exchange. He founded and served as a Board Member of Metrodora Therapeutics Inc.; a U.S. biotechnology company focused on systemic inflammation and the treatment of anemia. Mr. Mastrodonato is also the Founder and CEO of BMG Pharma, where he leads the development and global commercialization of innovative hyaluronic acid-based technologies across aesthetic dermatology. ophthalmology and osteoarthritis.

"I'm pleased to welcome Marco to our Board of Directors. Having worked with Marco for over 30 years, I know firsthand the depth of his global business acumen and his proven success across Europe and the Middle East." said Dr. Fred Sancilio, Lobe Sciences' Chairman and CEO.

About Lobe Sciences Ltd.

Lobe Sciences Ltd. is a clinical stage biopharmaceutical company focused on developing novel therapies for rare neurological and hematological conditions. The company operates through two subsidiaries:

• Cynaptec Pharmaceuticals, Inc. (a private Delaware company currently owned 64% by Lobe Sciences Ltd) is advancing Conjugated Psilocin (CP), a patented new chemical entity targeting Chronic Cluster Headache, for which it plans to seek an orphan indication. Substance use disorder (SUD) and possibly additional CNS disorders and other indications are under strategic review.

• Altemia, Inc. is addressing sickle cell disease with two complementary assets: a medical food currently in early-stage distribution, and S-100, a patent-pending therapeutic candidate designed to treat the underlying pathology of the disease.

Lobe's pipeline is differentiated by intellectual property, clinical momentum, and a strategic focus on high-value, underserved markets.

For additional Information, please contact:

Lobe Sciences Ltd.
[email protected]
www.lobesciences.com

Neither the "CSE" Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding "Forward-Looking" Information

This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the expectation that the Company will receive all necessary approvals to complete the Offering; the expectation that the Company will complete the Offering on the terms disclosed; and the intended use of proceeds of the Offering are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" or occur.

Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the Company will receive all necessary approvals to complete the Offering; that the Company will complete the Offering on the terms and timing anticipated; and that the proceeds from the Offering will be used as anticipated. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the Company will not receive the necessary approvals to complete the Offering; that the Company will not complete the Offering on the terms disclosed, or at all; and that the Company will be unable to use the proceeds received from the Offering.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

SOURCE: Lobe Sciences Ltd.

View the original press release on ACCESS Newswire

F.Tremblay--SMC